Hongene Biotech Corporation, a contract development and manufacturing organization (CDMO) specializing in nucleic acid therapeutics, today announced its critical role in advancing DNV001, a novel GalNAc-conjugated siRNA targeting dyslipidemia. The therapy, developed by Hangzhou Dingle Xinwei Biotechnology, recently received investigational new drug (IND) clearance from China’s Center for Drug Evaluation (acceptance number: CXHL2500095). Hongene provided […]
Post Type Archives: News
Quotient Sciences Announces Formation of Scientific Advisory Board
Quotient Sciences, a leading integrated CRDMO (contract research, development and manufacturing organization) for the pharmaceutical and biotech industry, is pleased to announce the formation of its Scientific Advisory Board (SAB) and appointment of inaugural members from the US, UK and Europe. The Quotient Sciences SAB was formed to enhance the Company’s commitment to scientific innovation […]
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of USD 222 billion over next 10 years Ongoing investment in in-house manufacturing to create end-to-end leading European biosimilar hub, capital expenditure commitments remain unchanged Most recent USD 440 million investment in new production plant in Brnik, due […]
Axplora announces further €35M expansion at Farmabios to double footprint and fuel long-term growth
Axplora is proud to unveil a transformative €35 million expansion at its Farmabios site in Gropello Cairoli, Italy, reinforcing the company’s longstanding commitment to serving the evolving needs of its customers through strategic investment and innovation. This latest investment builds on the €45 million already committed over the past five years, bringing Axplora’s total recent […]
Axplora announces further €35M expansion at Farmabios to double footprint and fuel long-term growth
Axplora is proud to unveil a transformative €35 million expansion at its Farmabios site in Gropello Cairoli, Italy, reinforcing the company’s longstanding commitment to serving the evolving needs of its customers through strategic investment and innovation. This latest investment builds on the €45 million already committed over the past five years, bringing Axplora’s total recent […]
Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency of each site. Both facilities undergoing expansions are essential components of Piramal Pharma’s integrated antibody-drug conjugate (ADC) offering, ADCelerate™, reflecting the company’s commitment to delivering innovative solutions that align with patient […]
Veranova Appoints Dr. Matteo Villain as Vice President of Peptides and Oligonucleotides
Veranova is pleased to announce the appointment of Dr. Matteo Villain as Vice President of Peptides and Oligonucleotides. Dr. Villain will bring extensive expertise in peptide and oligonucleotide development and manufacturing to Veranova as the company continues to strengthen its position as a key player in the Peptide and Oligonucleotide (TIDES) space. “Dr. Villain, and […]
Tanvex Biopharma USA, Inc
Tanvex BioPharma USA, Inc., a subsidiary of Tanvex BioPharma, Inc. and a contract development and manufacturing organization (CDMO) specializing in biologics under the brand Bora Biologics, is excited to announce a strategic license and supply agreement with Invagen Pharmaceuticals, Inc., a wholly owned subsidiary of Cipla Limited in United States (hereinafter referred as ‘Cipla’). This […]
Leading european biologics CDMO Mabion, releases first batch of Novalgen’s next-generation T-cell engager, NVG-222 for first in-human clinical trials
In a significant move to accelerate the global fight against blood cancers and hard-totreat solid tumours, renowned end-to-end biologics CDMO Mabion have entered into a strategic development and manufacturing partnership with London based NovalGen an existing client with whom cooperation under CDMO orders was first disclosed in current report No. 13/2024 dated August 16, 2024. […]
Vetter Marks the Start of New Clinical Site Construction with Groundbreaking Ceremony
Vetter, a leading, globally operating Contract Development and Manufacturing Organization (CDMO), celebrated the start of construction for its new clinical manufacturing site in Des Plaines with an official groundbreaking ceremony on June 26. The independent pharmaceutical service provider received the building permit for the new site in April of this year. With an investment of […]